18 March 2019

Amedeo Smart

Independent Medical Education

Subscriber: th..@boehringer-ingelheim.com

HIV Infection

18 March 2019 | n=50

  1. Cattin A, Salinas TRW, Gosselin A, Planas D, et al.
    HIV-1 is rarely detected in blood and colon myeloid cells during viral-suppressive antiretroviral therapy.
    AIDS 2019.

  2. Chevalier MF, Bhatnagar N, Didier C, Lopez-Gonzalez M, et al.
    gammadelta T-cell subsets in HIV controllers: potential role of Tgammadelta17 cells in the regulation of chronic immune activation.
    AIDS 2019.

  3. Davy-Mendez T, Napravnik S, Zakharova O, Wohl DA, et al.
    Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting.
    AIDS 2019.

  4. Leddy AM, Turan JM, Johnson MO, Neilands TB, et al.
    Poverty stigma is associated with suboptimal HIV care and treatment outcomes among women living with HIV in the U.S.
    AIDS 2019.

  5. Pilcher CD, Porco TC, Facente SN, Grebe E, et al.
    A generalizable method for estimating duration of HIV infections using clinical testing history and HIV test results.
    AIDS 2019.

  6. Saloner R, Heaton RK, Campbell LM, Chen A, et al.
    Effects of comorbidity burden and Age on brain integrity in HIV.
    AIDS 2019.

  7. Castagna A, Rusconi S, Gulminetti R, Bonora S, et al.
    Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy.
    AIDS 2019.

  8. Sanford R, Strain J, Dadar M, Maranzano J, et al.
    HIV infection and cerebral small vessel disease are independently associated with brain atrophy and cognitive impairment.
    AIDS 2019.

  9. Acharya A, Fonsah J, Mbanya DN, Njamnshi A, et al.
    Near-full length genetic characterization of a novel HIV-1 unique recombinant with similarities to A1, CRF01_AE and CRFO2_AG viruses in Yaounde, Cameroon.
    AIDS Res Hum Retroviruses 2019.

  10. Fatti G, Grimwood A, Nachega JB, Nelson JA, et al.
    Better Virological Outcomes amongst People Living with HIV Initiating Early Antiretroviral Treatment (CD4 counts >/= 500 cells/microL) in the HPTN 071 (PopART) Trial in South Africa.
    Clin Infect Dis 2019.

  11. Myer L, Redd AD, Mukonda E, Lynch BA, et al.
    Antiretroviral adherence, elevated viral load and drug resistant mutations in HIV-infected women initiating treatment in pregnancy: a nested case-control study.
    Clin Infect Dis 2019.

  12. Mehraj V, Ramendra R, Isnard S, Dupuy FP, et al.
    Circulating (1-->3)-beta-D-Glucan is associated with immune activation during HIV infection.
    Clin Infect Dis 2019.

  13. Salazar-Vizcaya L, Kusejko K, Schmidt AJ, Carrillo-Montoya G, et al.
    Clusters of sexual behaviour in HIV-positive men who have sex with men reveal highly dissimilar time trends.
    Clin Infect Dis 2019.

  14. Ronald LA, Campbell JR, Rose C, Balshaw R, et al.
    Estimated impact of World Health Organization latent tuberculosis screening guidelines in a low TB incidence region: retrospective cohort study.
    Clin Infect Dis 2019.

  15. Marr KA, Sun Y, Spec A, Lu N, et al.
    A Multicenter, Longitudinal Cohort Study of Cryptococcosis in HIV-Negative People in the United States.
    Clin Infect Dis 2019.

  16. Friedrich MJ.
    Higher HIV Rates in Adolescent Girls Related to Drought in Lesotho.
    JAMA 2019;321:1041.

  17. Neukam K, Fernandez MD, Quero JH, Rivero-Juarez A, et al.
    Response to hepatitis A virus vaccine in HIV-infected patients within a retrospective, multicentric cohort: Facing hepatitis A outbreaks in the clinical practice.
    J Acquir Immune Defic Syndr 2019.

  18. Revell AD, Wang D, Perez-Elias MJ, Wood R, et al.
    Predicting virological response to HIV treatment over time: a tool for settings with different definitions of virological response.
    J Acquir Immune Defic Syndr 2019.

  19. Twahirwa Rwema JO, Lyons CE, Ketende S, Bowring AL, et al.
    Characterizing the Influence of Structural Determinants of HIV Risk on Consistent Condom Use among female sex workers in Senegal.
    J Acquir Immune Defic Syndr 2019.

  20. Sacktor N, Saylor D, Nakigozi G, Nakasujja N, et al.
    Effect of HIV Subtype and Antiretroviral therapy on HIV-associated neurocognitive disorder (HAND) stage in Rakai, Uganda.
    J Acquir Immune Defic Syndr 2019.

  21. Gandhi M, Devi S, Bacchetti P, Chandy S, et al.
    Measuring adherence to antiretroviral therapy via hair concentrations in India.
    J Acquir Immune Defic Syndr 2019.

  22. Merlin JS, Long D, Becker WC, Cachay ER, et al.
    Marijuana Use is Not Associated with Changes in Opioid Prescriptions or Pain Severity Among People Living with HIV and Chronic Pain.
    J Acquir Immune Defic Syndr 2019.

  23. Johnson MO, Neilands TB, Koester KA, Wood T, et al.
    Detecting Disengagement from HIV Care Before It's Too Late: Development and Preliminary Validation of a Novel Index of Engagement in HIV Care.
    J Acquir Immune Defic Syndr 2019.

  24. Rao SG, Galaviz KI, Gay HC, Wei J, et al.
    Factors Associated with Excess Myocardial Infarction Risk in HIV-infected Adults: a Systematic Review and Meta-Analysis.
    J Acquir Immune Defic Syndr 2019.

  25. Bowler S, Chew GM, Budoff M, Chow D, et al.
    J Acquir Immune Defic Syndr 2019.

  26. Daniel Jacobus VH, Sa'ad L, Hendrick Jaco L, Mark Patrick N, et al.
    The real-world performance and inter-observer agreement of urine lipoarabinomannan in diagnosing HIV-associated tuberculosis in an emergency center.
    J Acquir Immune Defic Syndr 2019.

  27. Hoenigl M, Hassan A, Moore DJ, Anderson PL, et al.
    Predictors of Long Term HIV Pre Exposure Prophylaxis Adherence after Study Participation in Men who have Sex with Men.
    J Acquir Immune Defic Syndr 2019.

  28. Spinelli MA, Glidden DV, Anderson PL, Gandhi M, et al.
    Short-Term Adherence Marker to PrEP Predicts Future Non-Retention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.
    J Acquir Immune Defic Syndr 2019.

  29. Ross JL, Teeraananchai S, Lumbiganon P, Hansudewechakul R, et al.
    A longitudinal study of behavioral risk, adherence and virologic control in adolescents living with HIV in Asia.
    J Acquir Immune Defic Syndr 2019.

  30. Hill BJ, Rosentel K, Hebert L.
    Brief Report: Assessing the impact of race on HIV/STI risk perceptions among young men who have sex with men using an experimental approach.
    J Acquir Immune Defic Syndr 2019.

  31. Lipira L, Williams EC, Nevin PE, Kemp CG, et al.
    Religiosity, social support and ethnic identity: Exploring "resilience resources" for African-American women experiencing HIV-related stigma.
    J Acquir Immune Defic Syndr 2019.

  32. Margossian R, Williams PL, Yu W, Jacobson DL, et al.
    Markers of Bone Mineral Metabolism and Cardiac Structure and Function in Perinatally HIV-Infected and HIV-Exposed but Uninfected Children and Adolescents.
    J Acquir Immune Defic Syndr 2019.

  33. Schackman BR, Jeng PJ, Flash MJE, Mejia M, et al.
    Cost of an HIV Medical Care Coordination Program in Los Angeles County.
    J Acquir Immune Defic Syndr 2019.

  34. Gulhati V, Soo J, Ransy DG, Brophy J, et al.
    Brief Report: Higher Levels of Angiopoietin-1 Are Associated With Early and Sustained Viral Suppression in Children Living With Vertically Acquired HIV.
    J Acquir Immune Defic Syndr 2019;80:590-595.

  35. Montgomery ET, Atujuna M, Krogstad E, Hartmann M, et al.
    The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth.
    J Acquir Immune Defic Syndr 2019;80:542-550.

  36. Khosropour CM, Soge OO, Suchland R, Leipertz G, et al.
    Recurrent/intermittent vaginal and rectal chlamydial infection following treatment: a prospective cohort study among female STD clinic patients.
    J Infect Dis 2019.

  37. Lelievre JD.
    Preexposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption.
    J Infect Dis 2019.

  38. Aepfelbacher JA, Balmaceda J, Purdy J, Mattingly A, et al.
    Increased Prevalence of Hepatic Steatosis in Young Adults with Life-long HIV.
    J Infect Dis 2019.

  39. Leymarie O, Lepont L, Versapuech M, Judith D, et al.
    Contribution of the cytoplasmic determinants of Vpu to the expansion of virus containing compartments in HIV-1 infected macrophages.
    J Virol 2019.

  40. Skelton JK, Ortega-Prieto AM, Kaye S, Jimenez-Guardeno JM, et al.
    Kinetics of early innate immune activation during HIV-1 infection of humanized mice.
    J Virol 2019.

  41. Sharma S, Jafari M, Bangar A, William K, et al.
    The C-terminal end of HIV-1 viral protein U (Vpu) encodes a clade-specific determinant to antagonize BST-2 and facilitate virion release.
    J Virol 2019.

  42. Juno JA, Wragg KM, Kristensen AB, Lee WS, et al.
    Modulation of the CCR5 receptor/ligand axis by seminal plasma and the utility of in vitro versus in vivo models.
    J Virol 2019.

  43. Zhu Y, Chong H, Yu D, Guo Y, et al.
    Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
    J Virol 2019.

  44. Sherpa C, Jackson PEH, Gray LR, Anastos K, et al.
    Evolution of the HIV-1 RRE during natural infection reveals nucleotide changes that correlate with altered structure and increased activity over time.
    J Virol 2019.

  45. Page KR, Doocy S, Reyna Ganteaume F, Castro JS, et al.
    Venezuela's public health crisis: a regional emergency.
    Lancet 2019.

  46. The Lancet.
    Ending HIV in the USA.
    Lancet 2019;393:960.

  47. Saunders MJ, Evans CA.
    Ending Tuberculosis through Prevention.
    N Engl J Med 2019;380:1073-1074.

  48. Swindells S, Ramchandani R, Gupta A, Benson CA, et al.
    One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
    N Engl J Med 2019;380:1001-1011.

  49. Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, et al.
    A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med 2019.

  50. Waters LJ, Collins S, Boffito M.
    Guidelines in the context of medical ethics.
    BMJ 2019;364:l1040.

Display articles in

Amedeo HIV Infection

Data Origin

You selected the following journals for your Amedeo HIV Infection newsletter:

AIDS, AIDS Res Hum Retroviruses, Ann Intern Med, BMJ, Clin Infect Dis, J Acquir Immune Defic Syndr, J Clin Immunol, J Clin Invest, J Infect Dis, J Med Virol, J Virol, JAMA, Lancet, N Engl J Med, Nat Med, Pediatr Infect Dis J, Science, Virology.

To modify the journal selection, please open your Newsletter Management Page. If you don't remember the URL, please submit the email address of your Amedeo subscription.

Your email:

Amedeo HIV Infection

Five-Week Literature

14 October 2019

07 October 2019

30 September 2019

23 September 2019

16 September 2019

18 March 2019

Multidisciplinary Journal Club

  1. Dombkowski KJ, Cowan AE, Reeves SL, Foley MR, et al.
    The impacts of email reminder/recall on adolescent influenza vaccination.
    Vaccine. 2017 Apr 25. pii: S0264-410X(17)30511.

  2. Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, et al.
    HIV-1 remission following CCR5Delta32/Delta32 haematopoietic stem-cell transplantation.
    Nature. 2019 Mar 5. pii: 10.1038/s41586-019-1027.

  3. Thybo KH, Hagi-Pedersen D, Dahl JB, Wetterslev J, et al.
    Effect of Combination of Paracetamol (Acetaminophen) and Ibuprofen vs Either Alone on Patient-Controlled Morphine Consumption in the First 24 Hours After Total Hip Arthroplasty: The PANSAID Randomized Clinical Trial.
    JAMA. 2019;321:562-571.

Every week, Amedeo's Multidisciplinary Journal Club (MJC) presents a selection of outstanding articles. Take a look beyond the horizon.

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016